Healius flags Lumus sale, confirms Kate McKenzie as chair
Make us a preferred source
Make us a preferred source on Google
The news: Healthcare services provider Healius has put its diagnostic imaging unit Lumus Imaging on the market as it looks to bolster its national pathology and clinical trials business.
The numbers: Healius said it has started a formal process to sell Lumus after completing a review of its structure and assets that had been announced in March.
Healius shares were up 1.1% at $1.34 each in early trading on the ASX. The stock is down nearly 54% over the past 12 months.
The context: Healius has appointed UBS Securities Australia to assist with the sale of Lumus. CEO Paul Anderson said Lumus had a strong market position as one of Australia’s largest diagnostic imaging providers and recent investment and strategic initiatives were delivering strong growth in revenue and profitability.
Healius also said its board had unanimously appointed Kate McKenzie as its chair. McKenzie has served as interim chair since November last year after the resignation of permanent chair Jenny Macdonald.
What they said: “Realising value from Lumus will enable Healius to drive the earnings recovery in the company’s large-scale national pathology network and maximise growth in our clinical trials business, Agilex," Anderson said.
"Focusing on these businesses will reduce complexity and allow Healius to simplify our corporate cost base without impacting the quality of our services."
The source: ASX announcement
